Maekawa S, Suzuki H, Ohkubo K, Aoki Y, Okada T, Maeda H, Ogura K, Arai Y
Department of Urology, Kurashiki Central Hospital.
Hinyokika Kiyo. 2000 May;46(5):301-6.
Between November 1994 and July 1996, 45 patients with superficial bladder tumor were assigned to two groups before transurethral resection of bladder tumor. Twenty-one of the 45 patients were instilled with 20 mg epirubicin before endoscopic resection then continuously irrigated with 40 micrograms/ml epirubicin solution for 20 hours immediately after surgery; 24 of the 45 patients received continuous irrigation with saline in the same manner. The patients were assessed by cystoscopy and urinary cytology every 3 months during the first 2 years and every 6 months thereafter. One year recurrence-free rates in the treated and control groups were 56% and 32%, respectively. The recurrence-free period tended to be longer in the treated group than in the control group, although the difference was not significant (p = 0.17). One year recurrence-free rates in the treated and control groups for the patients with solitary tumor were 88% and 48%, respectively, the difference being marginally significant (p = 0.06). These results suggested that continuous bladder irrigation with epirubicin was effective for patients with a single tumor. Therefore, the long-term prophylactic therapy for a single tumor was an overtreatment. Prophylactic intravesical chemotherapy for superficial bladder cancer was proposed to be stratified by the number of tumors, single or multiple.
1994年11月至1996年7月期间,45例浅表性膀胱肿瘤患者在经尿道膀胱肿瘤切除术前行分组。45例患者中有21例在经内镜切除术前灌注20 mg表柔比星,术后立即用40μg/ml表柔比星溶液持续冲洗20小时;45例患者中有24例以同样方式接受生理盐水持续冲洗。在最初2年中每3个月通过膀胱镜检查和尿细胞学检查对患者进行评估,此后每6个月评估一次。治疗组和对照组的1年无复发生存率分别为56%和32%。治疗组的无复发期虽长于对照组,但差异无统计学意义(p = 0.17)。单发肿瘤患者治疗组和对照组的1年无复发生存率分别为88%和48%,差异有边缘统计学意义(p = 0.06)。这些结果提示,表柔比星持续膀胱冲洗对单发肿瘤患者有效。因此,对单发肿瘤进行长期预防性治疗属于过度治疗。建议对浅表性膀胱癌的预防性膀胱内化疗按肿瘤数量(单发或多发)进行分层。